par riluzole sun 50 mg film-coated tablets pl 31750 0010 ... · medicinal product riluzole sun 50...

Public Assessment Report

Decentralised Procedure

Riluzole SUN 50 mg Film-Coated Tablets

Procedure No: UK/H/2942/001/DC

UK Licence No: PL 31750/0010

SUN Pharmaceutical Industries Europe BV

Riluzole SUN 50 mg film-coated tablets UK/H/2942/001/DC

2

LAY SUMMARY On 09 February 2011, Germany, Spain, France, Italy, The Netherlands and the UK agreed to grant a Marketing Authorisation to Sun Pharmaceutical Industries Europe BV for the medicinal product Riluzole SUN 50 mg film-coated tablets (PL 31750/0010; UK/H/2942/001/DC). The licence was granted via the Decentralised Procedure (DCP), with the UK as Reference Member State (RMS). After a subsequent national phase, a Marketing Authorisation was granted in the UK on 07 March 2011. This is a prescription-only medicine (POM) used in the treatment of patients with amyotrophic lateral sclerosis (ALS). ALS is a form of motor neurone disease, where damage to the nerve cells responsible for sending instructions to the muscles leads to weakness, muscle wastage and paralysis. The destruction of nerve cells in motor neurone disease may be caused by too much glutamate (a chemical messenger) in the brain and spinal cord. Riluzole SUN 50 mg film-coated tablets contain the active ingredient riluzole, which belongs to a group of medicines that act on the nervous system. Riluzole stop the release of glutamate and this may help in preventing the nerve cells being damaged. No new or unexpected safety concerns arose from this application and it was, therefore, judged that the benefits of taking Riluzole SUN 50 mg film-coated tablets outweigh the risks and a Marketing Authorisation was granted.


3

TABLE OF CONTENTS

Module 1: Information about initial procedure Page 4 Module 2: Summary of Product Characteristics Page 5 Module 3: Product Information Leaflet Page 11 Module 4: Labelling Page 13 Module 5: Scientific Discussion Page 15 1 Introduction 2 Quality aspects 3 Non-clinical aspects 4 Clinical aspects 5 Overall conclusions Module 6 Steps taken after initial procedure


4

Module 1 Information about the initial procedure

Product Name

Riluzole SUN 50 mg film-coated tablets

Type of Application

Generic, Article 10.1

Active Substance

Riluzole

Form

Film-coated tablets

Strength

50 mg

MA Holder

Sun Pharmaceutical Industries Europe B.V. Polarisavenue 87 2132 JH Hoofddorp The Netherlands

Reference Member State (RMS)

UK

Concerned Member States (CMS)

Germany, Spain, France, Italy and The Netherlands

Procedure Number

UK/H/2942/001/DC

Timetable

Day 210 – 09 February 2011


5

Module 2 Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Riluzole SUN 50 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 50 mg of riluzole. For a full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Film-coated tablet. The tablets are white to off white coloured, round shape, biconvex, film coated tablets debossed with ‘538’ on one side and plain on the other side.

4 CLINICAL PARTICULARS 4.1 Therapeutic indications

Riluzole SUN is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS). Clinical trials have demonstrated that Riluzole SUN extends survival for patients with ALS (see section 5.1). Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free. There is no evidence that Riluzole SUN exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole SUN has not been shown to be effective in the late stages of ALS. Safety and efficacy of Riluzole SUN has only been studied in ALS. Therefore, Riluzole SUN should not be used in patients with any other form of motor neurone disease.

4.2 Posology and method of administration

Treatment with Riluzole SUN should only be initiated by specialist physicians with experience in the management of motor neurone diseases. The recommended daily dose in adults or elderly is 100 mg (50 mg every 12 hours). No significant increased benefit can be expected from higher daily doses. Special populations Children Riluzole SUN is not recommended for use in children, due to a lack of data on the safety and efficacy of riluzole in any neurodegenerative diseases occurring in children or adolescents. Patients with impaired renal function Riluzole SUN is not recommended for use in patients with impaired renal function, as studies at repeated doses have not been conducted in this population (see section 4.4). Elderly Based on pharmacokinetic data, there are no special instructions for the use of Riluzole SUN in this population. Patients with impaired hepatic function See section 4.3, section 4.4 and section 5.2.

4.3 Contraindications

-hypersensitivity to the active substance or to any of the excipients -hepatic disease or baseline transaminases greater than 3 times the upper limit of normal


6

-patients who are pregnant or breast-feeding. 4.4 Special warnings and precautions for use

Liver impairment Riluzole should be prescribed with care in patients with a history of abnormal liver function, or in patients with slightly elevated serum transaminases (ALT/SGPT; AST/SGOT up to 3 times the upper limit of the normal range (ULN)), bilirubin and/or gamma-glutamyl transferase (GGT) levels. Baseline elevations of several liver function tests (especially elevated bilirubin) should preclude the use of riluzole (see section 4.8). Because of the risk of hepatitis, serum transaminases, including ALT, should be measured before and during therapy with riluzole. ALT should be measured every month during the first 3 months of treatment, every 3 months during the remainder of the first year, and periodically thereafter. ALT levels should be measured more frequently in patients who develop elevated ALT levels. Riluzole should be discontinued if the ALT levels increase to 5 times the ULN. There is no experience with dose reduction or rechallenge in patients who have developed an increase of ALT to 5 times ULN. Re-administration of riluzole to patients in this situation cannot be recommended. Neutropenia Patients should be warned to report any febrile illness to their physicians. The report of a febrile illness should prompt physicians to check white blood cell counts and to discontinue riluzole in case of neutropenia (see section 4.8). Interstitial lung disease Cases of interstitial lung disease have been reported in patients treated with riluzole, some of them were severe (see section 4.8). If respiratory symptoms develop such as dry cough and/or dyspnea, chest radiography should be performed, and in case of findings suggestive of interstitial lung disease (e.g. bilateral diffuse lung opacities), riluzole should be discontinued immediately. In the majority of the reported cases, symptoms resolved after drug discontinuation and symptomatic treatment. Renal impairment Studies at repeated doses have not been conducted in patients with impaired renal function (see section 4.2).

4.5 Interaction with other medicinal products and other forms of interaction

There have been no clinical studies to evaluate the interactions of riluzole with other medicinal products. In vitro studies using human liver microsomal preparations suggest that CYP 1A2 is the principal isozyme involved in the initial oxidative metabolism of riluzole. Inhibitors of CYP 1A2 (e.g. caffeine, diclofenac, diazepam, nicergoline, clomipramine, imipramine, fluvoxamine, phenacetin, theophylline, amitriptyline and quinolones) could potentially decrease the rate of riluzole elimination, while inducers of CYP 1A2 (e.g. cigarette smoke, charcoal-broiled food, rifampicin and omeprazole) could increase the rate of riluzole elimination.

4.6 Pregnancy and lactation

Riluzole SUN is contraindicated (see section 4.3) in pregnancy (see section 5.3). Clinical experience with riluzole in pregnant women is lacking. Riluzole SUN is contraindicated (see section 4.3) in breast-feeding women (see section 5.3). It is not known whether riluzole is excreted in human milk.

4.7 Effects on ability to drive and use machines

Patients should be warned about the potential for dizziness or vertigo, and advised not to drive or operate machinery if these symptoms occur. No studies on the effects on the ability to drive and use machines have been performed.


7

4.8 Undesirable effects In phase III clinical studies conducted in ALS patients treated with riluzole, the most commonly reported adverse reactions were asthenia, nausea and abnormal liver function tests. Undesirable effects ranked under headings of frequency are listed below, using the following convention: very common (≥1/10) common (≥1/100 to <1/10) uncommon (≥1/1,000 to <1/100) rare (≥1/10,000 to <1/1,000) very rare (<1/10,000) not known (cannot be estimated from the available data). Blood and lymphatic system disorders Uncommon: anaemia Not known: severe neutropenia (see section 4.4) Immune system disorders Uncommon: anaphylactoid reaction, angioedema Nervous system disorders Common: headache, dizziness, oral paraesthesia and somnolence Cardiac disorders Common: tachycardia Respiratory, thoracic and mediastinal disorders Uncommon: interstitial lung disease (see section 4.4) Gastrointestinal disorders Very common: nausea Common: diarrhoea, abdominal pain, vomiting Uncommon: pancreatitis Hepatobiliary disorders Very common: abnormal liver function tests*. Increased alanine aminotransferase usually appeared

within 3 months after the start of therapy with riluzole; they were usually transient and levels returned to below twice the ULN after 2 to 6 months while treatment was continued. These increases could be associated with jaundice. In patients (n=20) from clinical studies with increases in ALT to more than 5times the ULN, treatment was discontinued and the levels returned to less than 2 times the ULN within 2 to 4 months in most cases (see section 4.4).

Not known: hepatitis General disorders and administration site conditions Very common: asthenia Common: pain *study data indicate that Asian patients may be more susceptible to liver function test abnormalities -3.2% (194/5995) of Asian patients and 1.8% (100/5641) of Caucasian patients.

4.9 Overdose

Neurological and psychiatric symptoms, acute toxic encephalopathy with stupor, coma, and methemoglobinemia have been observed in isolated cases. In case of overdose, treatment is symptomatic and supportive.


8

5 PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: other nervous system drugs, ATC code: N07XX02. Although the pathogenesis of ALS is not completely elucidated, it is suggested that glutamate (the primary excitatory neurotransmitter in the central nervous system) plays a role for cell death in the disease. Riluzole is proposed to act by inhibiting glutamate processes. The mode of action is unclear. Clinical trials In a trial, 155 patients were randomised to riluzole 100 mg/day (50 mg twice daily) or placebo and were followed-up for 12 to 21 months. Survival, as defined in the second paragraph of section 4.1, was significantly extended for patients who received riluzole as compared to patients who received placebo. The median survival time was 17.7 months versus 14.9 months for riluzole and placebo, respectively. In a dose-ranging trial, 959 patients with ALS were randomised to one of four treatment groups: riluzole 50, 100, 200 mg/day, or placebo and were followed-up for 18 months. In patients treated with riluzole 100 mg/day, survival was significantly higher compared to patients who received placebo. The effect of riluzole 50 mg/day was not statistically significant compared to placebo and the effect of 200 mg/day was essentially comparable to that of 100 mg/day. The median survival time approached 16.5 months versus 13.5 months for riluzole 100 mg/day and placebo, respectively. In a parallel group study designed to assess the efficacy and safety of riluzole in patients at a late stage of the disease, survival time and motor function under riluzole did not differ significantly from that of placebo. In this study the majority of patients had a vital capacity less than 60%. In a double-blind placebo-controlled trial designed to assess the efficacy and safety of riluzole in Japanese patients, 204 patients were randomised to riluzole 100 mg/day (50 mg twice daily) or placebo and were followed-up for 18 months. In this study, the efficacy was assessed on inability to walk alone, loss of upper limb function, tracheostomy, need for artificial ventilation, gastric tube feeding or death. Tracheostomy-free survival in patients treated with riluzole did not differ significantly from placebo. However, the power of this study to detect differences between treatment groups was low. Meta-analysis including this study and those described above showed a less striking effect on survival for riluzole as compared to placebo although the differences remained statistically significant.

5.2 Pharmacokinetic properties

The pharmacokinetics of riluzole have been evaluated in healthy male volunteers after single oral administration of 25 to 300 mg and after multiple-dose oral administration of 25 to 100 mg bid. Plasma levels increase linearly with the dose and the pharmacokinetic profile is dose-independent. With multiple dose administration (10 day-treatment at 50 mg riluzole bid), unchanged riluzole accumulates in plasma by about 2 fold and steady-state is reached in less than 5 days. Absorption Riluzole is rapidly absorbed after oral administration with maximal plasma concentrations occurring within 60 to 90 minutes (Cmax = 173 ± 72 (sd) ng/ml). About 90% of the dose is absorbed and the absolute bioavailability is 60 ± 18%. The rate and extent of absorption is reduced when riluzole is administered with high-fat meals (decrease in Cmax of 44%, decrease in AUC of 17%). Distribution Riluzole is extensively distributed throughout the body and has been shown to cross the blood brain barrier. The volume of distribution of riluzole is about 245 ± 69 l (3.4 l/kg). Riluzole is about 97% protein bound and it binds mainly to serum albumin and to lipoproteins. Metabolism Unchanged riluzole is the main component in plasma and is extensively metabolised by cytochrome P450 and subsequent glucuronidation. In vitro studies using human liver preparations demonstrated that cytochrome P450 1A2 is the principal isoenzyme involved in the metabolism of riluzole. The metabolites identified in urine are three phenolic derivatives, one ureido-derivative and unchanged riluzole.


9

The primary metabolic pathway for riluzole is initial oxidation by cytochrome P450 1A2 producing N-hydroxyriluzole (RPR112512), the major active metabolite of riluzole. This metabolite is rapidly glucuronoconjugated to O- and N-glucuronides. Elimination The elimination half-life ranges from 9 to 15 hours. Riluzole is eliminated mainly in the urine. The overall urinary excretion accounts for about 90% of the dose. Glucuronides accounted for more than 85% of the metabolites in the urine. Only 2% of a riluzole dose was recovered unchanged in the urine. Special populations Patients with impaired renal function There is no significant difference in pharmacokinetic parameters between patients with moderate or severe chronic renal insufficiency (creatinine clearance between 10 and 50 ml.min-1) and healthy volunteers after a single oral dose of 50 mg riluzole. Elderly The pharmacokinetic parameters of riluzole after multiple dose administration (4.5 days of treatment at 50 mg riluzole bid) are not affected in the elderly (> 70 years). Patients with impaired hepatic function The AUC of riluzole after a single oral dose of 50 mg increases by about 1.7 fold in patients with mild chronic liver insufficiency and by about 3 fold in patients with moderate chronic liver insufficiency. Race A clinical study conducted to evaluate the pharmacokinetics of riluzole and its metabolite N-hydroxyriluzole following repeated oral administration twice daily for 8 days in 16 healthy Japanese and 16 Caucasian adult males showed in the Japanese group a lower exposure of riluzole (Cmax 0.85 [90% CI 0.68-1.08] and AUCinf 0.88 [90% CI 0.69-1.13]) and similar exposure to the metabolite. The clinical significance of these results is not known.

5.3 Preclinical safety data

Riluzole did not show any carcinogenicity potential in either rats or mice. Standard tests for genotoxicity performed with riluzole were negative. Tests on the major active metabolite of riluzole gave positive results in two in vitro tests. Intensive testing in seven other standard in vitro or in vivo assays did not show any genotoxic potential of the metabolite. On the basis of these data, and taking into consideration the negative studies on the carcinogenesis of riluzole in the mouse and rat, the genotoxic effect of this metabolite is not considered to be of relevance in humans. Reductions in red blood cell parameters and/or alterations in liver parameters were noted inconsistently in subacute and chronic toxicity studies in rats and monkeys. In dogs, haemolytic anaemia was observed. In a single toxicity study, the absence of corpora lutea was noted at a higher incidence in the ovary of treated compared to control female rats. This isolated finding was not noted in any other study or species. All these findings were noted at doses which were 2-10 times higher than the human dose of 100 mg/day. Fertility studies in rats revealed slight impairment of reproductive performance and fertility at doses of 15 mg/kg/day (which is higher than the therapeutic dose), probably due to sedation and lethargy. In the pregnant rat, the transfer of 14C- riluzole across the placenta to the foetus has been detected. In rats, riluzole decreased the pregnancy rate and the number of implantations at exposure levels at least twice the systemic exposure of humans given clinical therapy. No malformations were seen in animal reproductive studies. In lactating rats, 14C-riluzole was detected in milk.


10

6 PHARMACEUTICAL PARTICULARS 6.1 List of excipients

Tablet core: Calcium hydrogen phosphate anhydrous (E341) Microcrystalline cellulose (E460) Povidone (K-30) (E1201) Croscarmellose sodium (E468) Colloidal anhydrous silica (E551) Talc Magnesium stearate (E572) Tablet coating: Opadry 03B68903 white consisting of: Hypromellose 6 cP Titanium dioxide (E171) Talc Macrogol 400

6.2 Incompatibilities

Not applicable. 6.3 Shelf life

24 months.

6.4 Special precautions for storage This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

Tablets are packaged in pvc/aluminium blister cards. Each package contains 56 tablets (4 blister cards of 14 tablets each). Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements

7 MARKETING AUTHORISATION HOLDER Sun Pharmaceutical Industries Europe B.V. Polarisavenue 87 2132 JH Hoofddorp The Netherlands

8 MARKETING AUTHORISATION NUMBER(S)

PL 31750/0010 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 07/03/2011 10 DATE OF REVISION OF THE TEXT

07/03/2011


11

Module 3


12


13

Module 4 Labelling


14

Module 5 Scientific discussion during initial procedure

I INTRODUCTION Based on the review of the data on quality, safety and efficacy, the member states considered that the application for Riluzole SUN 50 mg film-coated tablets (PL 31750/0010; UK/H/2942/001/DC) could be approved. The product is a prescription-only medicine (POM) indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS). This application was submitted using the Decentralised Procedure (DCP), with the UK as Reference Member State (RMS) and Germany, Spain, France, Italy and The Netherlands as Concerned Member States (CMS). The application was submitted under Article 10.1 of 2001/83/EC, as amended, claiming to be a generic medicinal product of Rilutek 50 mg film-coated tablets (Aventis Pharma SA, France), which was first approved in the EEA via the Centralised Procedure on 10 June 1996. The active ingredient riluzole belongs to a group of medicines which act on the nervous system. Although the pathogenesis of ALS is not completely elucidated, it is suggested that glutamate (the primary excitatory neurotransmitter in the central nervous system) plays a role for cell death in the disease. Riluzole is proposed to act by inhibiting glutamate processes. The mode of action is unclear. No non-clinical studies were conducted, which is acceptable given that the application was based on being a generic medicinal product of an originator product that has been licensed for over 10 years. One single-dose, bioequivalence study was submitted to support this application, comparing the test product Riluzole SUN 50 mg film-coated tablets with the reference product Rilutek 50 mg film-coated tablets (Aventis Pharma SA, France). The bioequivalence study was carried out in accordance with Good Clinical Practice (GCP). With the exception of this bioequivalence study, no new clinical studies were performed, which is acceptable given that the application was based on being a generic medicinal product of an originator product that has been licensed for over 10 years. The RMS has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place at all sites responsible for the manufacture, assembly and batch release of this product. For manufacturing sites outside the Community, the RMS has accepted copies of current GMP Certificates, satisfactory inspection summary reports, ‘close-out letters’ or ‘exchange of information’ issued by the inspection services of the competent authorities (or those countries with which the EEA has a Mutual Recognition Agreement for their own territories) as certification that acceptable standards of GMP are in place at those non-community sites. The RMS and CMS considered that the application could be approved at the end of procedure (Day 210) on 09 February 2011. After a subsequent national phase, the licence was granted in the UK on 07 March 2011.


15

II. ABOUT THE PRODUCT Name of the product in the Reference Member State

Riluzole SUN 50 mg film-coated tablets

Name(s) of the active substance(s) (INN)

Riluzole

Pharmacotherapeutic classification (ATC code)

Other nervous system drugs, (ATC code: N07X X02).

Pharmaceutical form and strength(s) Film-coated tablets 50 mg

Reference numbers for the Decentralised Procedure

UK/H/2942/001/DC

Reference Member State (RMS) United Kingdom

Concerned Member States (CMS) Germany, Spain, France, Italy and The Netherlands

Marketing Authorisation Number

PL 31750/0010

Name and address of the authorisation holder Sun Pharmaceutical Industries Europe B.V. Polarisavenue 87 2132 JH Hoofddorp The Netherlands


16

III SCIENTIFIC OVERVIEW AND DISCUSSION III.1 QUALITY ASPECTS ACTIVE SUBSTANCE INN: Riluzole Chemical names: 2-Amino-6-(trifluorornethoxy)benzothiazole Structure:

Molecular formula: C8H5N2F3S Molecular Mass: 234.20 Appearance: A white to slightly yellow powder, very soluble in methanol and freely

soluble in dichloromethane. At the time of the assessment of this application, riluzole was not the subject of a European Pharmacopoeia monograph. Synthesis of the active substance from the designated starting materials has been adequately described, and appropriate in-process controls and intermediate specifications are applied. Satisfactory specification tests are in place for all starting materials and reagents, and these are supported by relevant certificates of analysis. Appropriate proof-of-structure data have been supplied. All potential known impurities have been identified and characterised. An appropriate specification is provided for the active substance. Analytical methods have been appropriately validated and are satisfactory for ensuring compliance with the relevant specifications. Batch analysis data are provided and comply with the proposed specification. Satisfactory Certificates of Analysis have been provided for all working standards. Suitable specifications have been provided for all packaging used. The primary packaging has been shown to comply with current guidelines concerning contact with foodstuff. Appropriate stability data have been generated supporting a suitable retest period when stored in the proposed packaging. MEDICINAL PRODUCT Other Ingredients Other ingredients consist of the pharmaceutical excipients anhydrous calcium hydrogen phosphate (E341), microcrystalline cellulose (E460), povidone (K-30) (E1201), croscarmellose sodium (E468), colloidal anhydrous silica (E551), magnesium stearate (E572), talc (making up the tablet core), and Opadry 03B68903 white (the tablet coating). Opadry 03B68903 is made up of hypromellose 6 cP, titanium dioxide (E171), talc and macrogol 400. Appropriate justifications for the inclusion of each excipient have been provided.


17

With the exception of Opadry 03B68903 white, all excipients comply with their respective European Pharmacopoeia monograph. Opadry 03B68903 white is controlled to suitable a in-house specification. Satisfactory Certificates of Analysis have been provided for all excipients, showing compliance with the proposed specifications. None of the excipients contain materials of animal or human origin. No genetically modified organisms (GMO) have been used in the preparation of this product. Pharmaceutical Development The objective of the development programme was to formulate a safe, efficacious, stable product that could be considered a generic medicinal product of the reference product Rilutek 50 mg film-coated tablets (Aventis Pharma SA, France). Suitable pharmaceutical development data have been provided for this application. Comparative in-vitro dissolution and impurity profiles have been provided for this product and the reference product Rilutek 50 mg film-coated tablets (Aventis Pharma SA, France). Manufacturing Process A satisfactory batch formula has been provided for the manufacture of the product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated and has shown satisfactory results. Control of Finished Product The finished product specification proposed is acceptable. Test methods have been described and have been adequately validated. Batch data have been provided and comply with the release specification. Certificates of Analysis have been provided for all working standards used. Container-Closure System The product is packaged in polyvinylchloride/aluminium blister cards. These are packed into cardboard cartons with patient information leaflets in pack sizes of 56 film-coated tablets (four blister cards of 14 tablets each). Satisfactory specifications and Certificates of Analysis have been provided for all packaging components. All primary packaging complies with the current European regulations (Directive 2002/72/EC, as amended) concerning materials in contact with foodstuff. Stability of the Product Finished product stability studies were performed in accordance with current guidelines on batches of finished product packed in the packaging proposed for marketing. Based on the results, a shelf-life of 24 months has been proposed with no special storage conditions. Suitable post approval stability commitments have been provided to continue stability testing on batches of finished product.


18

Bioequivalence/Bioavailability Satisfactory Certificates of Analysis have been provided for the test and reference batches used in the bioequivalence study. Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), Labels The SmPC, PIL and labels are pharmaceutically acceptable. A package leaflet has been submitted to the MHRA along with results of consultations with target patient groups ("user testing"), in accordance with Article 59 of Council Directive 2001/83/EC, as amended. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains. MAA Form The MAA form is pharmaceutically satisfactory. Expert Report The pharmaceutical expert report has been written by an appropriately qualified person and is a suitable summary of the pharmaceutical aspects of the dossier. Conclusion The grant of a Marketing Authorisation is recommended.


19

III.2 NON-CLINICAL ASPECTS PHARMACODYNAMICS, PHARMACOKINETICS AND TOXICOLOGY As the pharmacodynamic, pharmacokinetic and toxicological properties of riluzole are well-known, no further non-clinical studies are required and none have been provided. NON-CLINICAL EXPERT REPORT The non-clinical expert report has been written by an appropriately qualified person and is a suitable summary of the non-clinical aspects of the dossier. ENVIRONMENTAL RISK ASSESSMENT A suitable justification has been provided for non-submission of an Environmental Risk Assessment. As the product is intended for generic substitution with a product that is already marketed, no increase in environmental burden is anticipated. Thus, the justification for non-submission of an Environmental Risk Assessment is accepted. CONCLUSION The grant of a Marketing Authorisation is recommended.


20

III.3 CLINICAL ASPECTS CLINICAL PHARMACOLOGY The clinical pharmacology of riluzole is well-known. With the exception of data from the below bioequivalence study, no new pharmacodynamic or pharmacokinetic data are provided or required for this application. Pharmacokinetics In support of the application, the Marketing Authorisation Holder submitted the following bioequivalence study: A randomised, open-label, two-treatment, two-sequence, two-period, single-dose, crossover study comparing the pharmacokinetics of the test product Riluzole SUN 50 mg film-coated tablets and the reference product Rilutek 50 mg film-coated tablets (Aventis Pharma SA, France) in healthy adult subjects under fasting conditions. The subjects were administered one tablet of test or reference product after at least a 10-hour fast. Blood samples were collected before and up to 24 hours after each administration. The washout period between the treatment arms was 7 days. The pharmacokinetic results are presented below:

Pharmacokinetic parameters (geometric mean, ratio and confidence intervals [CI]) of riluzole Parameters (units)

Riluzole Sun 50 mg (Test)

Rilutek 50 mg (Reference)

Test/Ref Ratio (%)

90% CI

AUC0-t (ng/ml*h)

408.71 423.55 96.50 87.32-106.63

AUC0-inf (ng/ml*h)

448.57 472.57 94.92 86.20-104.52

Cmax (ng/ml)

123.92 135.16 91.69 82.85-101.47

AUC0-t area under the plasma concentration-time curve from time zero to t hours AUC0-inf area under the plasma concentration-time curve from time zero to infinity Cmax maximum plasma concentration Ratios and 90% CI calculated from ln-transformed data The current Guidance on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 1) defines the confidence limits as 80% to 125% for Cmax and AUC values. The 90% confidence intervals of the test/reference ratio of geometric means for AUC0-t, AUC0-inf and Cmax lie within the acceptable limits. Thus, the data support the claim that the test product Riluzole SUN 50 mg film-coated tablets is bioequivalent to the reference product Rilutek 50 mg film-coated tablets (Aventis Pharma SA, France). Clinical pharmacology The clinical pharmacology of riluzole is well-known. No new pharmacodynamic or pharmacokinetic data are provided or required for this application. Efficacy The efficacy of riluzole is well-known. No new efficacy data have been submitted and none are required for an application of this type. Safety With the exception of the data generated during the bioequivalence study, no new safety data were submitted and none are required for this type of application. No new or unexpected safety issues were raised by the bioequivalence data.


21

Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL), Labels The SmPC, PIL and labels are clinically acceptable. The SmPC is consistent with that for the originator product. The PIL is consistent with the details in the SmPC and in-line with the current guidelines. The labelling is in-line with the current guidelines. Clinical Expert Report The clinical expert report has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier. Pharmacovigilance System and Risk Management Plan The Pharmacovigilance System, as described by the applicant, fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance, and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country. Suitable justification has been provided for not submitting a risk management plan for this product. Conclusion The grant of a Marketing Authorisation is recommended.


22

IV OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT QUALITY The important quality characteristics of Riluzole SUN 50 mg film-coated tablets are well-defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit-risk balance. NON-CLINICAL No new non-clinical data were submitted. As the pharmacokinetics, pharmacodynamics and toxicology of riluzole are well-known, no additional data were required. EFFICACY With the exception of the bioequivalence study, no new data were submitted and none are required for this type of application. Bioequivalence has been demonstrated between the applicant’s Riluzole SUN 50 mg film-coated tablets and the reference product Rilutek 50 mg film-coated tablets (Aventis Pharma SA, France). SAFETY With the exception of the bioequivalence study, no new data were submitted and none are required for this type of application. As the safety profile of riluzole is well-known, no additional data were required. No new or unexpected concerns arose from the safety data from the bioequivalence study. PRODUCT LITERATURE The SmPC, PIL and labelling are satisfactory, and consistent with those for the reference product, where appropriate, along with current guidelines. BENEFIT/RISK ASSESSMENT The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. Extensive clinical experience with riluzole is considered to have demonstrated the therapeutic value of the product. The benefit-risk is, therefore, considered to be positive.


23

Module 6

STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY

Date submitted

Application type

Scope Outcome

par riluzole sun 50 mg film-coated tablets pl 31750 0010 ... · medicinal product riluzole sun 50...

Documents